HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acrylates copolymer carcinogenic concern warrants risk assessment, panel concludes.

This article was originally published in The Rose Sheet

Executive Summary

ACRYLATES COPOLYMER CARCINOGENICITY CONCERN WARRANTS RISK ASSESSMENT, CIR concluded after reviewing new data submitted on the 34-chemical ingredient family at the panel's May 19 meeting in Washington, D.C. The Cosmetic Ingredient Review Expert Panel looked at two new studies that found a monomer, 2-ethylhexyl acrylate, contained in the acrylate VA copolymer had a "clearly carcinogenic effect" in mice treated with the monomer throughout their lifetimes. Based on these findings, the group tabled its ruling on the safety of the acrylates copolymer family and recommended a risk assessment be performed. The ingredients, found in 49y formulations, are used as binders and film formers in products such as lipstick, face powder and nail enamel.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel